Clinical Trials for Kidney Cancer

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors who have exhausted standard treatment options, testing the investigational single-agent ACTM-838 (mechanism of action not specified) as monotherapy. Eligible patients must have measurable disease, good performance status, adequate organ function, and CD4 counts >500/mL.

ClinicalTrials.gov ID: NCT06336148

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with GPC3-positive solid tumors (notably HCC; centrally confirmed by IHC) after standard therapies receive autologous GPC3-targeted CAR T cells armored with IL-15 and IL-21 to enhance expansion/persistence, incorporating an inducible caspase-9 safety switch, following cyclophosphamide/fludarabine lymphodepletion. Optional second infusion at 4 weeks if no progression.

ClinicalTrials.gov ID: NCT06198296

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Children and young adults (1–21 years) with relapsed/refractory GPC3-positive solid tumors (including HCC) receive cyclophosphamide/fludarabine lymphodepletion followed by a single infusion of autologous GPC3-targeted CAR T cells co-expressing IL-15 and IL-21, with an inducible caspase-9 safety switch. The investigational CAR targets the tumor proteoglycan GPC3, with IL-15/IL-21 “armoring” intended to enhance T-cell expansion and persistence.

ClinicalTrials.gov ID: NCT04715191

Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Maintenance cabozantinib (oral multi-kinase inhibitor of MET/VEGFR2/AXL/RET) for 12 months in children, adolescents, and young adults (≥18 months to <40 years) with ultra–high-risk solid tumors who have achieved at least stable disease after their most recent therapy and can start within 12 weeks. Includes strata such as neuroblastoma, metastatic Ewing sarcoma, osteosarcoma, high-risk rhabdomyosarcoma, DSRCT, and other high-risk sarcomas; single-arm, compared to historical controls.

ClinicalTrials.gov ID: NCT05135975

An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with progressive PSMA-positive mCRPC (ECOG 0–2) stratified by renal function (normal, moderate, severe impairment) receive lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617), a PSMA-targeted beta-emitting radioligand therapy, to assess biodistribution, dosimetry, PK, urinary excretion, and safety; dosing is 7.4 GBq q6 weeks (6 cycles for normal/moderate; 3 with possible extension in severe impairment). Excludes prior PSMA RLT and significant QT risk/medications during Cycle 1; all require PSMA-avid disease on 68Ga-PSMA-11 PET/CT.

ClinicalTrials.gov ID: NCT06004661

Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic urothelial carcinoma that progressed after prior enfortumab vedotin plus pembrolizumab are randomized to re-challenge with enfortumab vedotin (nectin-4–targeting ADC delivering MMAE) plus pembrolizumab (PD-1 inhibitor) with added therapeutic plasma exchange (days 1–3 of cycles 1–3) versus physician’s choice next-line standard of care. Eligible patients have measurable disease and ECOG 0–2; key exclusions include variant histologies (neuroendocrine, micropapillary, signet ring) and significant comorbidity.

ClinicalTrials.gov ID: NCT07087860

Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Single-arm study of olaparib, an oral PARP1/2 inhibitor, in adults with metastatic RCC (clear or non–clear cell) harboring pathogenic BAP1 or other DDR/HRR gene alterations (e.g., ATM, BRCA1/2, PALB2), after prior ICI and/or anti-VEGF therapy. Eligible patients require ECOG 0–1 and measurable disease; prior PARP inhibitor use and uncontrolled CNS disease are excluded.

ClinicalTrials.gov ID: NCT03786796

A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced/metastatic clear cell, translocation, or chromophobe RCC or urothelial carcinoma with measurable disease and prior progression on PD-1/PD-L1 (plus prior VEGFR TKI for RCC and chemo or ADC for UC) receive autologous cytokine-induced memory-like NK cells after lymphodepletion, supported by low-dose IL-2. CIML NK cells are ex vivo cytokine-activated NK cells designed to enhance innate antitumor cytotoxicity, cytokine production, and persistence; treated, stable brain metastases allowed.

ClinicalTrials.gov ID: NCT06318871